受体
抗原
BETA(编程语言)
淀粉样蛋白(真菌学)
β淀粉样蛋白
免疫学
计算生物学
生物
医学
神经科学
化学
分子生物学
生物化学
病理
计算机科学
肽
程序设计语言
作者
Cynthia J. Siebrand,Nicholas J. Bergo,Suckwon Lee,Julie Kay Andersen,Chaska C. Walton
标识
DOI:10.1186/s12967-025-06572-6
摘要
Abstract/Summary The lack of a definitive cure for Alzheimer’s disease (AD) is fueling the search for innovative therapeutic strategies. Having revolutionized cancer immunotherapy, immune cell engineering with chimeric antigen receptors (CAR) is being explored to target AD. Whether CARs can recognize distinct amyloid-β (Aβ) species and tau neurofibrillary tangles (NFTs)—hallmark pathologies of AD—remains unclear. To investigate this, we engineered CARs based on AD antibodies targeting tau (E2814), Aβ (Lecanemab and Aducanumab), and truncated pyroglutamate form of Aβ (Aβp3-42; Donanemab and Remternetug). To evaluate CAR function, we established the murine DO11.10 hybridoma T-cell line as a practical and scalable testing platform. Our findings demonstrate that CARs can detect and discriminate between tau preformed fibrils (PFFs), Aβ 1-42 , and Aβp3-42 aggregates. This highlights the potential of repurposing AD antibodies for CAR-based therapies to selectively target tau NFTs and distinct forms of Aβ senile plaques.
科研通智能强力驱动
Strongly Powered by AbleSci AI